Paion Ag PAIOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.05
- Day Range
- $0.05–0.05
- 52-Week Range
- $0.02–6.30
- Bid/Ask
- $0.00 / $1.00
- Market Cap
- $376,318.95
- Volume/Avg
- 3,105 / 12,902
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 64
- Website
- https://www.paion.com
Comparables
Valuation
|
Metric
|
PAIOF
|
HRPK
|
BFV
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 15.13 | 93.69 |
Price/Book Value | — | 0.85 | 6.99 |
Price/Sales | — | 2.76 | 5.42 |
Price/Cash Flow | — | 3.61 | — |
Price/Earnings
PAIOF
HRPK
BFV
Financial Strength
|
Metric
|
PAIOF
|
HRPK
|
BFV
|
|---|---|---|---|
Quick Ratio | 0.51 | 1.77 | 4.31 |
Current Ratio | 0.76 | 2.07 | 4.31 |
Interest Coverage | −5.02 | 3.29 | — |
Quick Ratio
PAIOF
HRPK
BFV
Profitability
|
Metric
|
PAIOF
|
HRPK
|
BFV
|
|---|---|---|---|
Return on Assets (Normalized) | −51.27% | 1.93% | 6.06% |
Return on Equity (Normalized) | −291.82% | 4.84% | 17.07% |
Return on Invested Capital (Normalized) | −63.45% | 3.07% | 11.95% |
Return on Assets
PAIOF
HRPK
BFV
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Hfkknksp | Kssr | $82.1 Bil | |||
| Merck KGaA ADR
MKKGY
| Bdngnxyf | Zwxry | $75.2 Bil | |||
| Haleon PLC ADR
HLN
| Mkqbkys | Krpc | $41.4 Bil | |||
| Viatris Inc
VTRS
| Pkjvyfx | Lkp | $14.4 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Vsvzgdrdw | Zds | $13.7 Bil | |||
| Catalent Inc
CTLT
| Nnwzpkzt | Bnyhzb | $10.6 Bil | |||
| Perrigo Co PLC
PRGO
| Rzqqhxrh | Bwkg | $3.8 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Hbcdszhp | Dtrhkqx | $3.5 Bil | |||
| Curaleaf Holdings Inc
CURLF
| Qnkmzzb | Svqx | $3.0 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Hnkmwpyq | Lzdr | $2.7 Bil |